metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
es-BC - HR-positive - 1st line (L1) breast cancer - HR positive es-BC - HR-positive - 1st line (L1)
versus letrozole
	taselisib plus letrozole
	LORELEI, 2019 Lancet Oncol 2019; 20:1226-1238-. NCT02273973	RCT	es-BC - HR-positive - 1st line (L1)	taselisib plus letrozole	placebo plus letrozole	Postmenopausal women (aged >= 18yr), with operable stage I-III invasive BC HR-positive (ER positive) and HER2-negative	166 / 168	low	suggested	suggested 55 % increase in objective responses (ORR) (PE) inconclusive 2.1-fold increase in pCR (PE)

Study

study type

Pathology

T1

T0

Patients

sample sizes

ROB

Results

RCT

es-BC - HR-positive - 1st line (L1)

taselisib plus letrozole

placebo plus letrozole

Postmenopausal women (aged >= 18yr), with operable stage I-III invasive BC HR-positive (ER positive) and HER2-negative

166 / 168